Samyang is a multinational conglomerate founded in South Korea in 1924, operating across diverse sectors including Biopharmaceuticals, Food, Chemicals, Packaging, and Cosmetics. Over the past decades, Samyang has built a strong foundation in drug delivery systems, leveraging its expertise in biodegradable polymers and polymeric micelle formulation technology. This dedication has led to the successful commercialization of modified anti-cancer generics and medical devices, earning global recognition for quality and safety. Currently, our primary focus is on the development of SENS™ (Selectivity Enabling Nano Shell) — a novel drug delivery platform designed for tissue-selective delivery of nucleic acid therapeutics. SENS™ is uniquely composed of biodegradable polymers and newly discovered cationic lipids. By adjusting composition and fine-tuning formulation processes, SENS™ enables targeted delivery of mRNA to specific tissues (e.g., spleen, lung, muscle, liver) while offering superior safety profiles that support repeat dosing. One of our key innovations, NanoReady, is a proprietary, ready-to-use SENS™ formulation. This pre-made nanoparticle system can be easily combined with mRNA immediately before administration, streamlining process development, reducing time-to-patient, and enabling personalized cancer vaccines. Through active collaboration with global partners, we are expanding our SENS™ platform across a range of mRNA-based therapeutics—including prophylactic and therapeutic cancer vaccines, protein replacement therapies, gene editing medicines, and more. We are actively seeking strategic partnerships with drug developers aiming to bring RNA therapies into the clinic. By combining their therapeutic innovations with our validated delivery modalities, we can enable safe and selective targeting, maximize clinical impact, and deliver novel therapies to patients.

Ritedose is the largest sterile CDMO in the U.S., specializing in Blow-Fill-Seal (BFS) technology for consistent, safe unit-dose delivery. From clinical trials to commercialization, Ritedose produces branded and generic inhalation and ophthalmic drugs, delivering high-quality, reliable medications that improve patient outcomes. Ritedose: Passion and Precision with a Purpose.

Therakind is a UK-based specialty pharmaceutical company that has successfully taken three products through FDA, EMA, and MHRA regulatory approval. It is developing its own dry powder intranasal drugs and collaborating with multiple partners on NCE and repurposing programmes leveraging its IP-protected proprietary DriDose® intranasal delivery technology. The platform enables rapid absorption without injection or breathing coordination and supports single-use and multidose reusable formats.

To learn more, please visit: https://the-patientview.com/

Mushroom Solutions specializes in AI-driven automation for clinical trials, regulatory affairs, and document processing. Our CTOps platform streamlines study design, decentralized trials, and compliance. With DocuGenX and hyperautomation tools, we empower sponsors, CROs, and sites to improve efficiency, reduce costs, and enhance participant experiences across the clinical research lifecycle. For more information, please visit https://mushroom.solutions

Trekka Therapeutics has developed CAPRO™, a novel biomaterial platform for drug delivery that overcomes the challenges associated with solubility, stability, loading and controlled release across a range of APIs including small-molecules, biologics (proteins, peptides, nucleic acids, vaccines) and combination drugs. CAPRO polymers are adaptable to various routes of administration and modified release dosage forms. They are also compatible with many existing excipients to form particulates, emulsions, gels and composites while the manufacturing is simple and highly scalable.

Clinical AI is a technology company specializing in the application of artificial intelligence in healthcare. For more information, please visit www.clinicalai.us 

Nelipak® is a leading of rigid and flexible packaging solutions for medical device, diagnostic, and pharma drug delivery and. To support the development of innovative sustainable packaging solutions, Nelipak offers in-house design, prototyping, and other value-added services as well as a line of tray sealing equipment. With 1,400 employees and 11 sites globally Nelipak is committed to delivering superior quality, service, and customer experience through world-class cleanroom manufacturing.

Cambridge Consultants (CC) is the deep tech powerhouse of Capgemini. Deep tech is a mindset, a bold strategy that harnesses radical science and engineering to achieve things no-one else can. It delivers transformative business value and growth for our clients, who gain defendable commercial and operational advantage from new-to-the-world products, services and processes that they own. We overcome the ultimate business challenge: turning something that doesn’t yet exist into a reality. Our advice is built on practice, with over 750 scientists, engineers, designers and consultants working globally across more than 20,000 sq m of state-of-the-art R&D facilities. As part of Capgemini Invent, CC is backed by 340,000+ Capgemini team members in more than 50 countries.

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million users trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. Discover more at www.medidata.com.

Daré’s mission is to challenge the status quo, making women’s health a priority. Our vision is to meet the increasing demand for evidence-based treatments with uncompromising scientific rigor and rapid, responsible commercialization. We aim to address decades of unmet needs by accelerating scientific innovation and bringing evidence-based treatment solutions from development to market.

Sempresto is developing an innovative, cell-phone integrated point-of-care delivery system for rescue medications, such as epinephrine for anaphylaxis, midazolam for epileptic seizures, naloxone for opioid overdose, and others. We firmly believe that the most effective medication is the one that is there when you need it, one that is compatible with your active lifestyle and difficult to leave behind.